The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1016/j.cell.2015.12.028

PMID

26824661

PICO

Population

1,122 adult diffuse grade II-III-IV gliomas from The Cancer Genome Atlas

Intervention

Comprehensive molecular profiling (whole-genome sequencing, DNA methylation, gene expression)

Comparator

Histopathological classification

Outcomes

Molecular classification, survival associations, telomere length correlations

Design

Type

Cross-sectional molecular analysis with survival correlation

Randomized

Multicenter

Yes

Blinded

Not applicable: molecular analysis

Follow-up

Retrospective survival data from TCGA

Primary endpoint

Identification of molecular subsets through DNA methylation profiling

Secondary endpoints

Association of molecular subsets with survival
Correlation of ATRX mutations with telomere length

Practice impact

What this means

This TCGA analysis of 1,122 diffuse gliomas uses molecular profiling to identify biologically discrete subsets. DNA methylation recapitulates IDH/1p19q classification and reveals new prognostic groups, including an IDH-mutant subset with poor outcome and an IDH-wildtype group resembling pilocytic astrocytoma. While not directly therapeutic, it strengthens the rationale for molecular classification in clinical decision-making.

Bottom line

Molecular profiling refines glioma classification beyond histology, identifying prognostically distinct subsets.

Strength of evidence

moderate

Recommendation

consider change

Why it matters

Large TCGA cohort provides robust molecular data
Supports integration of molecular markers into clinical practice
Retrospective design limits causal inference

What would change my mind

Prospective validation in independent cohorts
Clinical trials demonstrating treatment benefit based on molecular subsets
Standardization of methylation profiling across laboratories

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Low for molecular analysis; retrospective survival data subject to selection bias

Confounding

Clinical variables not fully adjusted in survival analyses

Missing data

Complete molecular data available for TCGA cohort; missing clinical details not specified

Multiplicity

Multiple hypothesis testing across genomic analyses without explicit correction

Notes

Large sample size enhances reliability
TCGA data standardization reduces technical variability

Stats check

NNT

N/A

Effect sizes

ATRX mutations associated with increased telomere length (p < 0.05)
IDH-mutant glioma subtype with poor outcome (p < 0.05)

Absolute effects

1,122 gliomas analyzed
IDH-wildtype subset with molecular similarity to pilocytic astrocytoma

Concerns

P-values reported without confidence intervals
No correction for multiple comparisons in genomic analyses

External validity

Who it applies to

Adult patients with diffuse gliomas (grades II-IV)

Who it does not

Pediatric gliomas, non-diffuse gliomas, non-TCGA populations

Generalizability notes

TCGA cohort represents academic centers; community practice may differ
Molecular classifications require specialized testing

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Summary

quote

We defined the complete set of genes associated with 1,122 diffuse grade II-III-IV gliomas from The Cancer Genome Atlas

claim_id

stats_check.effect_sizes

locator

p. 1 Summary

quote

ATRX but not TERT promoter mutations are associated with increased telomere length

claim_id

practice_impact.bottom_line

locator

p. 1 Summary

quote

Understanding of cohesive disease groups may aid improved clinical outcomes

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years